HighTower Advisors’s Adicet Bio ACET Stock Holding History

HighTower Advisors’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,345	Closed	-$1.33M	–	2283
2019 Q3	$1.33M	Buy	+1,345	New	+$1.5M	0.01%	1046

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighTower Advisors's ACET Position: Q4 2019 in Review

HighTower Advisors sold out of Adicet Bio (ACET) in Q4 2019, closing a stake of 1,345 shares — an estimated $1.33M sold.

HighTower Advisors first reported a position in ACET in Q3 2019 and held it in 1 quarter. The position peaked at $1.33M in Q3 2019. 54 funds tracked by Wall St. Rank hold ACET as of Q4 2019.

HighTower Advisors reported no remaining Adicet Bio position as of Q4 2019 after selling out during the quarter.
HighTower Advisors sold 1,345 Adicet Bio shares in Q4 2019, an estimated $1.33M.
HighTower Advisors first reported a position in Adicet Bio in Q3 2019 and held it in 1 quarter.
HighTower Advisors's Adicet Bio position peaked at $1.33M in Q3 2019.
54 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2019.

Based on HighTower Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.